EXPERIENCE WITH R-MINICHOP IN CLINICAL PRACTICE IN THE OLDEST PATIENTS WITH AGGRESSIVE NON HODGKIN?S LYMPHOMA
(Abstract release date: 05/19/16)
EHA Library. C. 06/09/16; 134643; PB1743
Carmen Julia
Contributions
Contributions
Abstract
Abstract: PB1743
Type: Publication Only
Background
About 40% of aggressive Non Hodgkin’s Lymphoma (NHL) are diagnosed in patients older than 70 years. However, the experience in the treatment of this group of patients is very limited. The encouraging results of the GELA group (Peyrade et al, Lancet Oncol 2011) with the R-miniCHOP regimen in patients older than 80 years suggest that a substantial proportion of them can be cured, and therefore it is recommended as the standard therapy in this population.
Aims
The aim of this study is to analyse our experience in using this regimen in elderly patients with aggressive lymphoma.
Methods
We retrospectively analysed patients consecutively diagnosed with aggressive NHL, older tan 70 years, treated with R-miniCHOP regimen (rituximab 375 mg/m2, cyclophosphamide 400 mg/m2, doxorubicin 25 mg/m2, vincristine 1 mg, prednisone 60 mg/day) in our center, from August 2010 to December 2015.
Results
Thirty patients who received at least 1 course of treatment were included in our analysis. Clinical characteristics are summarized in table 1. It is remarkable the poor prognosis of our patients, with median age of 81 years, the associated comorbidities and the high IPI. The median of treatment cycles received was 6 (1-8), 50% of cases received 6 cycles. Nine patients received prephase (Vincristine 1 mg and/or prednisone). Four patients received radiotherapy. Most frequent toxicity was hematological (grade 2 anemia and grade 3 afebrile neutropenia), ocurring mostly during the first cycle. Only one death occurred due to treatment toxicity (grade 4 neutropenia and sepsis). In seven patients, at least one cycle was postponed because of toxicity. The overall response rate was 63,3%, with 63,1% of patients achieving a complete response. During treatment, 11 patients experienced progression, 10 died and one reached partial response after salvage therapy with R-GEMOX (5 cycles). One death occurred because of other causes (arterial hemorrhage secondary to traumatism). During follow-up, three patients relapsed, with a median duration of response of 29.3 months. With a median follow-up of 17.15 months, median survival has not yet been reached (graphic 1). Table 1. Patient’s characteristics
Conclusion
R-miniCHOP represents an effective and safe regimen in this group of patients, confirming the previous experience of the GELA group. Toxicity observed in the first cycle shows the need of administering prephase in all patients.
Session topic: E-poster
Keyword(s): Chemotherapy, Elderly, Non-Hodgkin's lymphoma, Reduced intensity
Type: Publication Only
Background
About 40% of aggressive Non Hodgkin’s Lymphoma (NHL) are diagnosed in patients older than 70 years. However, the experience in the treatment of this group of patients is very limited. The encouraging results of the GELA group (Peyrade et al, Lancet Oncol 2011) with the R-miniCHOP regimen in patients older than 80 years suggest that a substantial proportion of them can be cured, and therefore it is recommended as the standard therapy in this population.
Aims
The aim of this study is to analyse our experience in using this regimen in elderly patients with aggressive lymphoma.
Methods
We retrospectively analysed patients consecutively diagnosed with aggressive NHL, older tan 70 years, treated with R-miniCHOP regimen (rituximab 375 mg/m2, cyclophosphamide 400 mg/m2, doxorubicin 25 mg/m2, vincristine 1 mg, prednisone 60 mg/day) in our center, from August 2010 to December 2015.
Results
Thirty patients who received at least 1 course of treatment were included in our analysis. Clinical characteristics are summarized in table 1. It is remarkable the poor prognosis of our patients, with median age of 81 years, the associated comorbidities and the high IPI. The median of treatment cycles received was 6 (1-8), 50% of cases received 6 cycles. Nine patients received prephase (Vincristine 1 mg and/or prednisone). Four patients received radiotherapy. Most frequent toxicity was hematological (grade 2 anemia and grade 3 afebrile neutropenia), ocurring mostly during the first cycle. Only one death occurred due to treatment toxicity (grade 4 neutropenia and sepsis). In seven patients, at least one cycle was postponed because of toxicity. The overall response rate was 63,3%, with 63,1% of patients achieving a complete response. During treatment, 11 patients experienced progression, 10 died and one reached partial response after salvage therapy with R-GEMOX (5 cycles). One death occurred because of other causes (arterial hemorrhage secondary to traumatism). During follow-up, three patients relapsed, with a median duration of response of 29.3 months. With a median follow-up of 17.15 months, median survival has not yet been reached (graphic 1). Table 1. Patient’s characteristics
| Characteristics | n = 30 |
| Age, median | 81 yo (73-85) |
| Women | 18 |
Comorbidities
| 15435 |
Histology
| 2523 |
| Stage III-IV | 21 |
IPI
| 34518 |
Conclusion
R-miniCHOP represents an effective and safe regimen in this group of patients, confirming the previous experience of the GELA group. Toxicity observed in the first cycle shows the need of administering prephase in all patients.
Session topic: E-poster
Keyword(s): Chemotherapy, Elderly, Non-Hodgkin's lymphoma, Reduced intensity
Abstract: PB1743
Type: Publication Only
Background
About 40% of aggressive Non Hodgkin’s Lymphoma (NHL) are diagnosed in patients older than 70 years. However, the experience in the treatment of this group of patients is very limited. The encouraging results of the GELA group (Peyrade et al, Lancet Oncol 2011) with the R-miniCHOP regimen in patients older than 80 years suggest that a substantial proportion of them can be cured, and therefore it is recommended as the standard therapy in this population.
Aims
The aim of this study is to analyse our experience in using this regimen in elderly patients with aggressive lymphoma.
Methods
We retrospectively analysed patients consecutively diagnosed with aggressive NHL, older tan 70 years, treated with R-miniCHOP regimen (rituximab 375 mg/m2, cyclophosphamide 400 mg/m2, doxorubicin 25 mg/m2, vincristine 1 mg, prednisone 60 mg/day) in our center, from August 2010 to December 2015.
Results
Thirty patients who received at least 1 course of treatment were included in our analysis. Clinical characteristics are summarized in table 1. It is remarkable the poor prognosis of our patients, with median age of 81 years, the associated comorbidities and the high IPI. The median of treatment cycles received was 6 (1-8), 50% of cases received 6 cycles. Nine patients received prephase (Vincristine 1 mg and/or prednisone). Four patients received radiotherapy. Most frequent toxicity was hematological (grade 2 anemia and grade 3 afebrile neutropenia), ocurring mostly during the first cycle. Only one death occurred due to treatment toxicity (grade 4 neutropenia and sepsis). In seven patients, at least one cycle was postponed because of toxicity. The overall response rate was 63,3%, with 63,1% of patients achieving a complete response. During treatment, 11 patients experienced progression, 10 died and one reached partial response after salvage therapy with R-GEMOX (5 cycles). One death occurred because of other causes (arterial hemorrhage secondary to traumatism). During follow-up, three patients relapsed, with a median duration of response of 29.3 months. With a median follow-up of 17.15 months, median survival has not yet been reached (graphic 1). Table 1. Patient’s characteristics
Conclusion
R-miniCHOP represents an effective and safe regimen in this group of patients, confirming the previous experience of the GELA group. Toxicity observed in the first cycle shows the need of administering prephase in all patients.
Session topic: E-poster
Keyword(s): Chemotherapy, Elderly, Non-Hodgkin's lymphoma, Reduced intensity
Type: Publication Only
Background
About 40% of aggressive Non Hodgkin’s Lymphoma (NHL) are diagnosed in patients older than 70 years. However, the experience in the treatment of this group of patients is very limited. The encouraging results of the GELA group (Peyrade et al, Lancet Oncol 2011) with the R-miniCHOP regimen in patients older than 80 years suggest that a substantial proportion of them can be cured, and therefore it is recommended as the standard therapy in this population.
Aims
The aim of this study is to analyse our experience in using this regimen in elderly patients with aggressive lymphoma.
Methods
We retrospectively analysed patients consecutively diagnosed with aggressive NHL, older tan 70 years, treated with R-miniCHOP regimen (rituximab 375 mg/m2, cyclophosphamide 400 mg/m2, doxorubicin 25 mg/m2, vincristine 1 mg, prednisone 60 mg/day) in our center, from August 2010 to December 2015.
Results
Thirty patients who received at least 1 course of treatment were included in our analysis. Clinical characteristics are summarized in table 1. It is remarkable the poor prognosis of our patients, with median age of 81 years, the associated comorbidities and the high IPI. The median of treatment cycles received was 6 (1-8), 50% of cases received 6 cycles. Nine patients received prephase (Vincristine 1 mg and/or prednisone). Four patients received radiotherapy. Most frequent toxicity was hematological (grade 2 anemia and grade 3 afebrile neutropenia), ocurring mostly during the first cycle. Only one death occurred due to treatment toxicity (grade 4 neutropenia and sepsis). In seven patients, at least one cycle was postponed because of toxicity. The overall response rate was 63,3%, with 63,1% of patients achieving a complete response. During treatment, 11 patients experienced progression, 10 died and one reached partial response after salvage therapy with R-GEMOX (5 cycles). One death occurred because of other causes (arterial hemorrhage secondary to traumatism). During follow-up, three patients relapsed, with a median duration of response of 29.3 months. With a median follow-up of 17.15 months, median survival has not yet been reached (graphic 1). Table 1. Patient’s characteristics
| Characteristics | n = 30 |
| Age, median | 81 yo (73-85) |
| Women | 18 |
Comorbidities
| 15435 |
Histology
| 2523 |
| Stage III-IV | 21 |
IPI
| 34518 |
Conclusion
R-miniCHOP represents an effective and safe regimen in this group of patients, confirming the previous experience of the GELA group. Toxicity observed in the first cycle shows the need of administering prephase in all patients.
Session topic: E-poster
Keyword(s): Chemotherapy, Elderly, Non-Hodgkin's lymphoma, Reduced intensity
{{ help_message }}
{{filter}}